Metabolic actions of angiotensin receptor antagonists: PPAR-γ agonist actions or a class effect?

Current Opinion in Pharmacology

Volumn 7, Issue 2, 2007, Pages 140-145

  Ernsberger, Paul ^a   Koletsky, Richard J ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT;

BINDING AFFINITY; CLINICAL TRIAL; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; HYPOTHESIS; IN VITRO STUDY; LIPID METABOLISM; LIPOPHILICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BIPHENYL COMPOUNDS; HUMANS; HYPERTENSION; PPAR GAMMA; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES;

EID: 33947115888     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.11.008     Document Type: Review

References (58)

1. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
2. Moller D.E., and Kaufman K.D. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 56 (2005) 45-62
3. Reaven G.M. The metabolic syndrome: requiescat in pace. Clin Chem 51 (2005) 931-938
4. Lindholm L.H., Persson M., Alaupovic P., Carlberg B., Svensson A., and Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 21 (2003) 1563-1574
5. Velliquette R.A., and Ernsberger P. Contrasting metabolic effects of antihypertensive agents. J Pharmacol Exp Ther 307 (2003) 1104-1111
6. Brook R.D. Mechanism of differential effects of antihypertensive agents on serum lipids. Curr Hypertens Rep 2 (2000) 370-377
7. Ernsberger P., and Koletsky R.J. Metabolic effects of antihypertensive agents: role of sympathoadrenal and renin-angiotensin systems. Naunyn Schmiedebergs Arch Pharmacol 373 (2006) 245-258
8. Koletsky R.J., Velliquette R.A., and Ernsberger P. The role of I(1)-imidazoline receptors and alpha(2)-adrenergic receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X. Ann N Y Acad Sci. 1009 (2003) 251-261
9. Bernobich E., De Angelis L., Lerin C., and Bellini G. The role of the angiotensin system in cardiac glucose homeostasis: therapeutic implications. Drugs 62 (2002) 1295-1314
10. De Champlain J. Do angiotensin II antagonists provide benefits beyond blood pressure reduction?. Adv Ther 22 (2005) 117-136
11. Opie L.H., and Schall R. Old antihypertensives and new diabetes. J Hypertens 22 (2004) 1453-1458
12. Jandeleit-Dahm K.A., Tikellis C., Reid C.M., Johnston C.I., and Cooper M.E. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 23 (2005) 463-473. Reviews clinical trial data as well as advancing possible mechanisms for the anti-diabetic actions of ARBs and ACE inhibitors in experimental models, including hemodynamic effects and alterations in glucose transport and insulin signaling mediated by inhibition of the RAS. The anti-inflammatory actions of ARBs and ACE inhibitors are also reviewed. All of these effects are accounted for in terms of interfering with the actions of angiotensin II.
13. Erlich Y., and Rosenthal T. Contribution of bradykinin to the beneficial effects of ramipril in the fructose-fed rat. J Cardiovasc Pharmacol 31 (1998) 581-584
14. Ura N., Higashiura K., and Shimamoto K. The mechanisms of insulin sensitivity improving effects of angiotensin converting enzyme inhibitor. Immunopharmacology 44 (1999) 153-159
15. Cosentino F., Savoia C., De Paolis P., Francia P., Russo A., Maffei A., Venturelli V., Schiavoni M., Lembo G., and Volpe M. Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists. Am J Hypertens 18 (2005) 493-499
16. Gletsu N., Doan T.N., Cole J., Sutliff R.L., and Bernstein K.E. Angiotensin II-induced hypertension in mice caused an increase in insulin secretion. Vascul Pharmacol 42 (2005) 83-92
17. Ramracheya R.D., Muller D.S., Wu Y., Whitehouse B.J., Huang G.C., Amiel S.A., Karalliedde J., Viberti G., Jones P.M., and Persaud S.J. Direct regulation of insulin secretion by angiotensin II in human islets of Langerhans. Diabetologia 49 (2006) 321-331
18. Carlsson P.O., Berne C., and Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 41 (1998) 127-133
19. Leung P.S., and Carlsson P.O. Pancreatic islet renin angiotensin system: its novel roles in islet function and in diabetes mellitus. Pancreas 30 (2005) 293-298
20. Tahmasebi M., Puddefoot J.R., Inwang E.R., and Vinson G.P. The tissue renin-angiotensin system in human pancreas. J Endocrinol 161 (1999) 317-322
21. Chu K.Y., Lau T., Carlsson P.O., and Leung P.S. Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 55 (2006) 367-374
22. Damas J., Garbacki N., and Lefebvre P.J. The kallikrein-kinin system, angiotensin converting enzyme inhibitors and insulin sensitivity. Diabetes Metab Res Rev 20 (2004) 288-297
23. Assimacopoulos-Jeannet F.D., Blackmore P.F., and Exton J.H. Studies of the interaction between glucagon and alpha-adrenergic agonists in the control of hepatic glucose output. J Biol Chem 257 (1982) 3759-3765
24. Hsieh P.S., Tai Y.H., Loh C.H., Shih K.C., Cheng W.T., and Chu C.H. Functional interaction of AT1 and AT2 receptors in fructose-induced insulin resistance and hypertension in rats. Metabolism 54 (2005) 157-164
25. Morgan N.G., Exton J.H., and Blackmore P.F. Angiotensin II inhibits hepatic cAMP accumulation induced by glucagon and epinephrine and their metabolic effects. FEBS Lett 153 (1983) 77-80
26. Reinhart P.H., Taylor W.M., and Bygrave F.L. Studies on alpha-adrenergic-induced respiration and glycogenolysis in perfused rat liver. J Biol Chem 257 (1982) 1906-1912
27. Ran J., Hirano T., and Adachi M. Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Am J Physiol Endocrinol Metab 287 (2004) E227-E232
28. Mancia G., Dell'oro R., Quarti-Trevano F., Scopelliti F., and Grassi G. Angiotensin-sympathetic system interactions in cardiovascular and metabolic disease. J Hypertens Suppl 24 (2006) S51-S56
29. Fink G.D. Long-term sympatho-excitatory effect of angiotensin II: a mechanism of spontaneous and renovascular hypertension. Clin Exp Pharmacol Physiol 24 (1997) 91-95
30. 1 receptor blockade prolongs the lifespan of spontaneously hypertensive rats and reduces stress-induced release of catecholamines, glucocorticoids, and vasopressin. Ann N Y Acad Sci 1018 (2004) 131-136
31. Ernsberger P., Koletsky R.J., and Friedman J.E. Contribution of sympathetic nervous system overactivity to cardiovascular and metabolic disease. Rev Contemp Pharmacother 9 (1998) 411-428
32. Henriksen E.J., and Jacob S. Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance. Diabetes Obes Metab 5 (2003) 214-222
33. Takai S., Kirimura K., Jin D., Muramatsu M., Yoshikawa K., Mino Y., and Miyazaki M. Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res 28 (2005) 593-600
34. Engeli S., Schling P., Gorzelniak K., Boschmann M., Janke J., Ailhaud G., Teboul M., Massiera F., and Sharma A.M. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?. Int J Biochem Cell Biol 35 (2003) 807-825
35. Sharma A.M., Janke J., Gorzelniak K., Engeli S., and Luft F.C. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 40 (2002) 609-611
36. 2 receptors.
37. Di Filippo C., Lampa E., Tufariello E., Petronella P., Freda F., Capuano A., and D'Amico M. Effects of irbesartan on the growth and differentiation of adipocytes in obese zucker rats. Obes Res 13 (2005) 1909-1914
38. Kurtz T.W. New treatment strategies for patients with hypertension and insulin resistance. Am J Med 119 (2006) S24-S30. This is a thorough and up-to-date review of telmisartan as both a PPAR-γ agonist and as an ARB, and the possible role of this dual mechanism of action on the prevention of diabetes and cardiovascular disease in humans.
39. Kurtz T.W. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol 42 Suppl 1 (2005) S9-S16
40. Schupp M., Janke J., Clasen R., Unger T., and Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109 (2004) 2054-2057
41. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., Qi N., Wang J., Avery M.A., and Kurtz T.W. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43 (2004) 993-1002
42. Li Y.-Q., Ji H., Ding D.Y., and Ye X.L. Metabolic effects of telmisartan in spontaneously hypertensive rats. Naunyn-Schmiedeberg's Archives of Pharmacology 373 (2006) 264-270
43. Araki K., Masaki T., Katsuragi I., Tanaka K., Kakuma T., and Yoshimatsu H. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension 48 (2006) 51-57
44. Ran J., Hirano T., Fukui T., Saito K., Kageyama H., Okada K., and Adachi M. Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance. Metabolism 55 (2006) 478-488
45. Koh K.K., Quon M.J., Han S.H., Chung W.J., Lee Y., and Shin E.K. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol 108 (2006) 96-100
46. Yenicesu M., Yilmaz M.I., Caglar K., Sonmez A., Eyileten T., Acikel C., Kilic S., Bingol N., Bingol S., and Vural A. Blockade of the renin-angiotensin system increases plasma adiponectin levels in type-2 diabetic patients with proteinuria. Nephron Clin Pract 99 (2005) c115-c121
47. Clasen R., Schupp M., Foryst-Ludwig A., Sprang C., Clemenz M., Krikov M., Thone-Reineke C., Unger T., and Kintscher U. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 46 (2005) 137-143
48. Doggrell S.A. Telmisartan - killing two birds with one stone. Expert Opin Pharmacother 5 (2004) 2397-2400
49. Kakuta H., Sudoh K., Sasamata M., and Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 25 (2005) 41-46
50. Sharma A.M. Telmisartan: the ACE of ARBs?. Hypertension 47 (2006) 822-823
51. Usui I., Fujisaka S., Yamazaki K., Takano A., Murakami S., Yamazaki Y., Urakaze M., Hachiya H., Takata M., Senda S., Iwata M., Satoh A., Sasaoka T., Ak N.D., Temaru R., and Kobayashi M. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Diabetes Res Clin Pract (2007)
52. Benndorf R.A., Rudolph T., Appel D., Schwedhelm E., Maas R., Schulze F., Silberhorn E., and Boger R.H. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 55 (2006) 1159-1164
53. Nagel J.M., Tietz A.B., Goke B., and Parhofer K.G. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism 55 (2006) 1149-1154
54. Janke J., Schupp M., Engeli S., Gorzelniak K., Boschmann M., Sauma L., Nystrom F.H., Jordan J., Luft F.C., and Sharma A.M. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation. J Hypertens 24 (2006) 1809-1816. This article is of outstanding interest because it demonstrates for the first time that telmisartan regulates the differentiation of human adipocytes.
55. Yoshida T., Yamagishi S., Nakamura K., Matsui T., Imaizumi T., Takeuchi M., Koga H., Ueno T., and Sata M. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia (2006)
56. Link A., Lenz M., Legner D., Bohm M., and Nickenig G. Telmisartan inhibits beta2-integrin MAC-1 expression in human T-lymphocytes. J Hypertens 24 (2006) 1891-1898
57. Takaya T., Kawashima S., Shinohara M., Yamashita T., Toh R., Sasaki N., Inoue N., Hirata K., and Yokoyama M. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis 186 (2006) 402-410
58. Erbe D.V., Gartrell K., Zhang Y.L., Suri V., Kirincich S.J., Will S., Perreault M., Wang S., and Tobin J.F. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul Pharmacol 45 (2006) 154-162